Biotherapeutics Discovery. End-to-End.
Genedata Biologics® streamlines discovery of biotherapeutics including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs. The most widely adopted platform across the industry, it integrates all discovery workflows so you can focus on true innovation.
One of the reasons we chose Genedata Biologics was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system.
Sergio Rotstein, Ph.D.
Director of Research Business Technology
Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow.
Dominik Maurer, Ph.D.
We are excited to implement the Genedata Biopharma Platform as a central integrated data backbone to streamline the capture, integration, democratization, and analysis of increasingly complex and diverse data types across Genmab’s discovery and clinical workflows.
Hisham Hamadeh, Ph.D.
VP, Global Head of Data Sciences
We undertook a thorough selection process to find the best antibody workflow platform and Genedata Biologics was the obvious choice.
Miguel Teodoro, Ph.D.
Head of IT Research
Genedata Biologics was the clear choice as a backbone system to support the full diversity of our complex and rapidly evolving antibody discovery processes.
Dennis Underwood, Ph.D.
VP Molecular and Information Systems
We chose Genedata Biologics because its built-in business logic avoids costly software customization and it’s a proven off-the-shelf-product that can be implemented quickly and replace our current processes.
Adam Clarke, Ph.D.
We made a decision early on to use Genedata Biologics as MorphoSys’ workflow backbone to accelerate our drug discovery efforts and have watched as Genedata Biologics has become the global industry standard for biopharma discovery organizations.
Markus Enzelberger, Ph.D.
Senior VP and Head of Discovery, Alliances and Technologies
Genedata seamlessly integrates into an existing research informatics environment and supports the full process through automation, standardization, and integration.
Senior Director of R&D Informatics
Genedata Biologics is a key component of our growth plans in the immuno-oncology and next-generation ADC space.
Thomas Sandal, Ph.D.
Vice President, R&D
Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization.
Tim Holmström, Ph.D.
Head of Biologics
The Genedata solution is now an integral part of our R&D infrastructure, supporting our efforts to develop novel biopharmaceuticals for hard-to-drug therapeutic targets.
Aaron Sato, Ph.D.
Chief Scientific Officer
A commercial data management solution such as this has been sorely lacking in protein therapeutics.
Clive Wood, Ph.D.
Head of Global Biologics
We appreciate Genedata Biologics’ flexible business model, which made it possible for a company of our size to adopt a market-leading platform solution.
Genedata Biologics will be our central repository for mission-critical data on therapeutic candidates such as bioactivity, developability, and manufacturability, and will enable transparent decision-making on candidates to move forward.
Bjoern Hock, Ph.D.
Director, Global Head Protein Engineering and Antibody Technologies
Thanks to Genedata’s flexible business model, we are able to take advantage of Genedata’s unique technology under terms that work well for a company of our size.
Glenn A. Friedrich, Ph.D.
Chief Operating Officer
Built from the Start for Biologics.
Accelerate research with a first-in-class platform uniquely designed from the start to digitalize biotherapeutic discovery. The platform facilitates complex R&D processes by designing, tracking, testing, and assessing novel biotherapeutics drugs. It works with any format, from antibodies, bi- or multi-specifics, ADCs, novel scaffolds, and therapeutic proteins, to engineered therapeutic cell lines such as TCRs and CAR-T cells.
E2E. A Next-Generation Platform.
Acting as a central end-to-end data backbone, Genedata Biologics integrates all R&D processes, from library design and immunizations, selections and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, to candidate developability and manufacturability assessments. With its scalable and modular architecture, it fully automates the discovery process and manages the highest data volumes. As a shared platform, it facilitates collaboration among different sites and groups and external partners such as CROs. Real-time access to all relevant data enables users at all levels of an organization to rapidly make more informed decisions, as well as analyze data patterns to drive future discovery programs.
Less Tedious Daily Work.
Genedata Biologics dramatically simplifies all day-to-day laboratory activities such as cloning, screening, expression, purification, and sample management and automates all data upload, data processing, and reporting. Direct integration with laboratory instruments and robotics stations enables true high-throughput processes. Customers report more than 50% gains in efficiency and improved quality of results.
Optimize Resources. Increase
Productivity. Eliminate Risks.
Providing a central and shared platform, Genedata Biologics gives every R&D team access to all discovery program information for any project at any time. This makes it possible to simultaneously investigate across projects to track program progress and optimize resource usage to improve R&D forecasting, reduce costs, and improve overall productivity.